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Abstract
Background: Fat redistribution, increased inflammation and insulin resistance are prevalent in non-diabetic subjects treated
with maintenance dialysis. The aim of this study was to test whether pioglitazone, a powerful insulin sensitizer, alters body
fat distribution and adipokine secretion in these subjects and whether it is associated with improved insulin sensitivity.
Trial Design: This was a double blind cross-over study with 16 weeks of pioglitazone 45 mg vs placebo involving 12
subjects.
Methods: At the end of each phase, body composition (anthropometric measurements, dual energy X-ray absorptometry
(DEXA), abdominal CT), hepatic and muscle insulin sensitivity (2-step hyperinsulinemic euglycemic clamp with 2H2-glucose)
were measured and fasting blood adipokines and cardiometabolic risk markers were monitored.
Results: Four months treatment with pioglitazone had no effect on total body weight or total fat but decreased the visceral/
sub-cutaneous adipose tissue ratio by 16% and decreased the leptin/adiponectin (L/A) ratio from 3.6361023 to 0.7661023.
This was associated with a 20% increase in hepatic insulin sensitivity without changes in muscle insulin sensitivity, a 12%
increase in HDL cholesterol and a 50% decrease in CRP.
Conclusions/Limitations: Pioglitazone significantly changes the visceral-subcutaneous fat distribution and plasma L/A ratio
in non diabetic subjects on maintenance dialysis. This was associated with improved hepatic insulin sensitivity and a
reduction of cardio-metabolic risk markers. Whether these effects may improve the outcome of non diabetic end-stage
renal disease subjects on maintenance dialysis still needs further evaluation.
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Introduction
Patients with ESRD on maintenance dialysis are prone to body
fat redistribution with an excess of visceral adipose tissue (VAT),
relative to subcutaneous adipose tissue (SAT). This pattern of fat
distribution is associated with dyslipidemia [1] and inflammatory
cytokine production [2], all intimately linked with insulin
resistance (IR). Abdominal obesity, as well as truncal fat
distribution without obesity, predict all cause and cardiovascular
mortality in patients with ESRD [3].
Furthermore, adipose tissue accumulation coupled with low
glomerular filtration rate may lead to the accumulation of plasma
adipokines. Among adipokines, lower levels of adiponectin have
been associated with the development of IR, whereas leptin is
directly correlated with body fat and nutritional intake [4,5]. In
ESRD, leptin accumulates to a much larger extent than
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adiponectin, thus producing an elevated plasma leptin to
adiponectin (L/A) ratio [6]. Plasma L/A ratio is identified as the
best correlate of IR measured by the hyperinsulinemic euglycemic
clamp (HEGC) in African American patients with ESRD on
maintenance hemodialysis [7]. The L/A plasma ratio is also
considered as an atherogenic index in the general population [8],
and in patients with type 2 diabetes (T2DM) [9]. Thus, a high L/A
ratio in ESRD may play a pivotal role in the pathogenesis of both
IR and cardiovascular complications in ESRD.
Glitazones are effective insulin sensitizers available in clinical
practice and their use is associated with significant and favourable
changes in body fat distribution and adipokine profile in subjects
with T2DM [10]. Furthermore, glitazones have also been shown
to improve glucose metabolism in diabetic and non diabetic ESRD
subjects [11–13]. Whether these effects are related to glitazone-
induced changes in body fat distribution or to changes in blood L/
A ratio is not known.
The aim of this study was to evaluate whether pioglitazone
alters body fat distribution and the L/A ratio in non diabetic
subjects on maintenance dialysis, and whether this was associated
with alterations in insulin sensitivity. Pioglitazone significantly
changed the visceral-subcutaneous fat distribution and plasma L/
A while improving hepatic insulin sensitivity.
Subjects and Methods
The study design was double blind randomized cross-over with
2 phases (Figure 1) and conducted at the University Hospital of
Lausanne, Switzerland (CHUV). In 2007, it received the approvals
from the local Ethics Committee (Human Research Ethics
Committee, Lausanne) and from Swissmedic (Swiss Agency for
Therapeutic Products) according to the principles expressed in the
declaration of Helsinki. At the time of the submission, the local
ethics committee did not require the registration in ClinicalTrial.-
gov. For this reason, the trial was registered only while it was
ongoing in 2010 under ClinicalTrial.gov NCT01253928. The
protocol for this trial and supporting CONSORT checklist are
available as supporting information; see Checklist S1 and Protocol
S1 and S2. This manuscript focuses exclusively on data of body
composition, adipokines, glucose metabolism and insulin resis-
tance. Non diabetic patients with ESRD treated for more than 3
months in the dialysis centre of the CHUV and in related centers
of the Canton de Vaud, were recruited after informed and written
consent. Recruitment took place between 2008–2010 and followed
up until 2011. Diabetic patients were excluded to prevent the
confounding factor of insulin treatment on IR assessment. Other
exclusion criteria were: estimated survival less than 6 months,
active infection, hospitalization within 1 month before the study,
congestive heart failure NYHA class III–IV and abnormal liver
function tests. The sample size chosen for this pilot study was
consistent with other studies having used this technique in this
population [7,14,15]. For this study, twelve subjects were included,
of which 8 were on hemodialysis (HD; age: 59.664.4 years) and 4
on peritoneal dialysis (PD, age: 43.563.6 years). The average body
mass index (BMI) was of 27.260.74 kg/m2 (range: 24.0–30.5 kg/
m2).
Each subject underwent the 2 treatment phases lasting 16 weeks
each, separated by a wash-out period of at least 2 weeks (Figure 1).
The sequence of treatment was randomized following allocation to
random numbers with the objective to have an equal number of
individuals starting with pioglitazone or placebo. The medical staff
providing the random allocation sequence differed from those
blinded for the treatment allocation involved in the recrutement,
and interventions. For those starting with the pioglitazone phase,
the following 18 week period without treatment (washout and
placebo phase) was considered sufficient to avoid a significant
carry-over effect of the pioglitazone phase. A similar design was
used recently in a study examining the effects of pioglitazone on
insulin sensitivity and sub-cutaneous adipose cell morphology [16].
The primary outcome was changes in visceral/subcutaneous
abdominal fat distribution. Secondary outcomes were changes in
the L/A ratio, in hepatic and muscle insulin sensitivity and in
biochemical cardiovascular risk markers.
At the end of each treatment, subjects underwent anthropo-
metric [17] and DEXA measurements and an abdominal CT scan
at the level of L4–L5 for the measurement of abdominal fat
distribution. For HD patients, these measurements were per-
formed immediately after an HD session, whereas for PD patients,
they were performed after the morning PD effluent drainage.
During the whole study, subjects were followed by their
nephrologist. For HD patients, dry body weight and ultrafiltration
rates (UF) were recorded at each HD session. A clinical
examination was performed once a week with special focus on
the presence of lower extremity edema and on other signs of fluid
overload. For PD patients, dry weight was recorded each morning
at bedside and daily UF rates were registered. Patients were
instructed to report each PD exchange and solutions on a flow
sheet. Patients were seen every 4 weeks by their nephrologist who
performed a clinical examination with special focus on the
presence of lower extremity edema and on other signs of fluid
overload. In addition, a weekly phone call was made to the subject
to check for potential side-effects and/or signs of fluid overload.
Metabolic investigations
Subjects reported at 0700 am to the metabolic unit, after a 10 h
overnight fast. HD patients were investigated in the metabolic unit
the day following an HD session. PD patients were investigated
after their first PD exchange in the morning. On arrival, subjects
were asked to empty their bladder and body composition was
estimated from subcutaneous skin-fold measurements at the
biceps, triceps, subscapular and suprailiac sites [17]. An indwelling
catheter was inserted into an antecubital vein of the right wrist for
repeated blood sampling. A second indwelling catheter was
inserted into an antecubital vein of the other arm for glucose,
insulin and tracer infusions. If the patient had an arteriovenous
fistula placed on the upper limb, this was accessed using a 16
gauge fistula needle for infusions of glucose, insulin and tracers,
and the blood sampling catheter was placed on the other side.
Blood was collected at baseline for the measurement of plasma
concentrations of glucose, insulin, total, HDL and LDL choles-
terol, triglycerides, CRP, IL-6, leptin and adiponectin. Monthly
measurements of serum albumin (immunonephelemetry), creati-
nine, and normalized protein catabolic rate (nPCR) were provided
by the dialysis centers in order to complete the assessment of
nutritional status and to estimate daily protein intake.
Methods for the 2-step hyperinsulinemic euglycemic
clamp. Liver and muscle IS were measured for 3 h after the
initial 2 h tracer infusion. A 2-step hyperinsulinemic euglycemic
clamp (0.03 mU ? kg21 ?min21 and 1 mU ? kg21 ?min21, 90 min
each), was performed and aimed to achieve a glycemia of
5.5 mmol/l, regardless of the patients’ fasting blood glucose.
Blood samples were collected every 5 min during the clamp to
monitor plasma glucose concentration and at 30 min intervals for
the analysis of tracers and insulin. Glucose metabolism was
assessed during the 2-step clamp with the continuous infusion of
6,6-[2H2]glucose infusion (Cambridge Isotope Laboratories, Inc.
Andover, MA; bolus: 2 mg/kg; continuous 20 mg ? kg21 ? min21)
and the plasma measurements of 6,6-[2H2]glucose. Substrate
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oxidation was measured by indirect calorimetry (ventilated
canopy) from 0800 to 1300 [18] by using the equations of Livesey
and Elia [19].
Glucose appearance rates were calculated at baseline and
during moderate and high insulinemia from plasma 6,6 2H2
glucose Steele’s equations for steady state conditions [20].
Endogenous glucose production (EGP) was identical with glucose
appearance rate in fasting conditions. During hyperinsulinemia,
EGP was computed as (glucose appearance rate) - (glucose infusion
rate). Since all measurements were done under steady state
conditions, total glucose disposal rate was considered as equal to
glucose appearance.
Analytical determinations
Plasma was immediately separated from blood by centrifugation
at 4uC for 10 min at 3600 rpm and stored at 220uC. Commercial
radioimmunoassy kits were used to measure plasma insulin, leptin,
and adiponectin (LINCO Research, St Charles, MO). During the
clamp, plasma glucose concentrations were measured by the
glucose oxidase method with a Beckman glucose analyzer II
(Beckman Instruments, Fullerton, CA). Plasma 6,6-[2H2]glucose
isotopic enrichment was measured by gas chromatography-mass
spectrometry (Hewlett-Packard Instruments), as previously de-
scribed [21]. Breath 13CO2 isotopic enrichment was determined
by Isotope Ratio Mass Spectrometry (IR/MS) on a Tracermass
C/N (SerCon Ltd, Crewe, Cheshire, UK). The homeostatic model
assessment of insulin resistance index (HOMA-IR) and the
HOMA corrected by adiponectin index (HOMA-AD) were
calculated according to published formulas [7].
Statistical Analysis
Because dialysis patients are heterogeneous, we chose to
perform a cross-over design instead of a case-control study. This
design increases the power of the study as each individual
examined serves as their own control. Taking into account the
Figure 1. Flow chart of the double blinded cross-over study.
doi:10.1371/journal.pone.0109134.g001
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within patient standard deviation and expected differences
between treatments for body fat distribution and for adiponectin
plasma levels based on previous studies using the same dosage of
pioglitazone and same duration of study [10,22], a sample size of
12 individuals was chosen with a projected drop-out rate of 10–
20% to reach the respectively 10 and 7 patients required to detect
a treatment difference for body fat distribution (primary end point)
and adiponectin plasma levels. At the end of each period
(pioglitazone and placebo), absolute values of parameters were
paired and compared as in previous publications using the same
design [16,23,24]. Data were expressed as mean 6 SEM. The
statistical differences between the 2 periods of treatment (placebo
and pioglitazone) were analysed by the paired Student’s t test using
the Minitab software. A level of p,0.05 was considered
statistically significant. The analysis of variance (ANOVA) for
paired comparisons was performed to examine an overall effect of
treatment during the clamp studies and whether the sequence of
treatments influenced the response to treatment (carry over effect).
The residual method was used when examining the effects of
pioglitazone while adjusting for co-variables. Briefly, this proce-
dure uses a linear regression to assess the effect of confounders on
the dependent variable, and then computes the residual (difference
between observed and predicted value). The residuals were then
compared using a standard paired t-test.
Results
Nine subjects completed both phases of the study (Table 1).
Two HD subjects dropped out of the study due to kidney
transplantation. One PD subject dropped out because of
peritonitis and subsequently switched to HD.
Body Composition
The body composition of subjects, at termination of each phase,
is presented in Table 2. Pioglitazone had no effect on total body
weight, but significantly decreased abdominal VAT and the VAT/
SAT ratio (mean 6 SEM; n=9, placebo: 0.6960.09, pioglita-
zone: 0.5860.09, p = 0.002). After stratification for dialysis
modality, in HD patients VAT/SAT ratio was of (mean 6
SEM; n= 6) placebo: 0.8460.06, pioglitazone: 0.7260.07,
p = 0.01. In PD patients VAT/SAT ratio was of (mean 6 SEM;
n=3) placebo: 0.3760.1, pioglitazone: 0.2960.04, p = 0.2. These
changes were similar in both dialysis modalities although it did not
reach a significant level in PD because of the small number of
observations. Subscapular subcutaneous fat deposition significant-
ly increased. In contrast, there was no effect on lean mass, and on
bone mineral density (BMD).
Fasting blood chemistry
Table 3 summarizes the biochemical analysis at termination of
each phase. Plasma albumin, creatinine and nPCR were not
affected by pioglitazone. HDL cholesterol increased significantly
with pioglitazone. There was a trend toward a decrease in CRP
and IL-6 plasma levels in accordance with a study performed in
hemodialysis patients [25,26]. Under pioglitazone, plasma leptin
concentrations significantly decreased, whereas plasma adiponec-
tin significantly increased, thus resulting in a dramatically
suppressed L/A ratio (Figure 2; mean 6 SEM; n= 9, placebo:
3.6361.04, pioglitazone: 0.7660.25, p= 0.008). These effects
remained significant when adjusting the L/A ratio to visceral fat,
total glucose disposal rate (GDR), or hepatic glucose output. After
stratification for dialysis modality, in HD patients L/A ratio was of
(mean 6 SEM; n= 6) placebo: 3.8561.37, pioglitazone:
0.7960.32, p = 0.039. In PD patients L/A ratio was of (mean 6
SEM; n= 3) placebo: 3.1861.88, pioglitazone: 0.6960.5, p = 0.2.
These changes were similar in both dialysis modalities although it
did not reach a significant level in PD patients because of the small
number of observations.
Glucose homeostasis (Table 3, Figure 3)
Pioglitazone significantly decreased fasting blood glucose and
HOMA-IR was lower with pioglitazone than with placebo (resp.
1.7560.2 vs 2.360.3; p = 0.05). Hepatic glucose output (endog-
enous glucose production) was significantly decreased (220.6%,
Figure 3a) with pioglitazone at baseline, demonstrating an
improvement in hepatic IS with pioglitazone. This difference
was maintained, although not significantly, at low and high dose
insulin infusion rates. There was a trend towards an increase in the
hepatic insulin sensitivity index (HISI, +56.8%, p= 0.06). As at
baseline, GDR is equivalent to hepatic glucose production, the
effects of insulin on GDR are only presented during the insulin
infusion steps (Figure 3b). At low dose and high dose insulin
infusion rates, pioglitazone did not significantly improve GDR. As
expected, glucose oxidation was increased with insulin infusion
(Figure 3c). Pioglitazone did not influence glucose oxidation at
baseline or during insulin infusions.
In order to evaluate a possible carry-over effect, we compared
the values of VAT and L/A ratio among subjects starting with the
Table 1. Characteristics of subjects enrolled and having completed both phases.
Subject Age Sex Ethnicity Cause of ESRD
Duration of
dialysis (months) Dialysis modality
1 68 M W Ischemic nephropathy and renal cholesterol emboli 52 HD
2 71 M W IgA nephropathy 61 HD
3 53 M A Obstructive uro-nephropathy 17 HD
4 79 M W Hypertensive nephroangiosclerosis 49 HD
5 57 M W Post-streptococcal Glomerulo-nephritis 124 HD
6 40 M W Polycystic kidney disease 42 HD
7 39 F W Reflex uro-nephropathy 35 PD
8 42 F W Membrano-proliferative glomerulonephritis 37 PD
9 54 M W Hypertensive nephroangiosclerosis 40 PD
M: male, F: female, W:White, A: African, HD: hemodialysis, PD: peritoneal dialysis.
doi:10.1371/journal.pone.0109134.t001
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Table 2. Body composition measurements at termination of placebo and pioglitazone phases.
Placebo Pioglitazone Diff (95%CI) P
Weight (kg) 78.462.2 78.162.4 0.35 (20.7;1.4)
Delta weight from start to end of phase 0.5160.48 0.6960.35 20.18 (21.7;1.3)
BMI (kg/m2) 2760.8 26.760.8 0.2 (20.3;0.8)
Waist circumference (cm) 103.662.9 103.663.3 0 (21.2;1.2)
Subscapular skinfold (cm) 1661.2 19.161.5 23.1 (26.0;20.2) 0.04
Biceps skinfold (cm) 9.361.6 8.061.6 1.39 (21.2;4.0)
Triceps skinfold (cm) 20.662.7 19.162.5 1.6 (21.0;4.1)
Brachial muscular circumference (mm) 272.264.6 27164.8 1.3 (24.6;7.1)
DEXA measurements
DEXA fat (kg) 26.162.1 25.762.2 0.4 (21.1;1.8)
DEXA fat (%) 33.362.5 33.162.8 0.2 (21.5;1.9)
DEXA leg fat (kg) 7.860.9 8.161.0 20.2 (20.7;0.3)
DEXA arm fat (kg) 2.960.4 3.160.4 20.17 (20.5;0.12)
Lean mass (kg) 49.962.3 49.862.4 0.2(21.0;1.4)
Lean mass: leg (kg) 15.460.9 15.160.9 0.3 (20.2;0.7)
Lean mass: arm (kg) 4.760.6 5.360.4 20.7 (21.9;0.6)
BMD (g/cm2) 1.0960.03 1.0960.03 0 (20.02;0.01)
BMD spine (g/cm2) 0.9260.03 0.9460.05 20.01 (20.10;0.07)
BMD pelvis (g/cm2) 1.0860.06 1.0860.05 0 (20.03;0.03)
BMD arm (g/cm2) 1.4460.16 1.6360.05 20.20 (20.65;0.26)
Abdominal CT scan measurements
VAT (cm2) 18.362.8 15.962.8 2.3 (0.9;3.8) 0.005
SAT (cm2) 27.662.4 28.562.7 20.9 (22.3;0.6)
VAT/SAT ratio 0.6960.09 0.5860.09 0.11 (0.05;0.12) 0.002
VAT: visceral adipose tissue area; SAT: subcutaneous adipose tissue area, DEXA: dual energy X-ray absorptiometry, BMD: bone mineral density.
doi:10.1371/journal.pone.0109134.t002
Table 3. Biochemistry values at termination of placebo and pioglitazone phases.
Placebo Pioglitazone Diff (95%CI) P
Cholesterol (mmol/l) 3.9960.21 3.9960.21 20.03 (20.43;0.37)
HDLcholesterol (mmol/l) 0.6560.06 0.7360.04 20.09 (20.17;0) 0.047
Triglyceride (mmol/l) 1.4760.17 1.6760.18 20.19(20.62;0.23)
LDL cholesterol (mmol/l) 2.8160.25 2.5360.29 0.28 (20.1;0–65)
Albumine (g/l) 40.062.2 39.161.9 1.0 (23.7;5.6)
nPCR (g/kg/day) 0.9960.10 1.0360.12 20.04 (20.16;0.08)
Creatinine (mmol/l) 800664 819663 219 (292;54)
CRP (mg/l) 7.8862.56 3.9661.44 3.92 (20.44;8.28) 0.07
IL-6 (pg/ml) 6.1164.4 3.662.5 2.52 (22.34;7.39)
Glucose (mmol/l) 5.160.2 4.860.1 0.3 (0.03;0.6) 0.04
Insulin (mU/ml) 9.861.3 8.160.8 1.8 (20.2;3.8)
HOMA-IR 2.360.3 1.7560.2 0.5 (0;1) 0.05
HOMA-AD 120635 46614 74.7 (218.7;168.1)
Leptin (ng/ml) 54.0616.5 36.7615.9 17.3 (0.87;33.7) 0.04
Adiponectin (mg/ml) 22.665.1 49.169.0 226.5 (251.8;1.2) 0.04
Leptin/Adiponectin ratio 3.636102361.0461023 0.766102360.2561023 2.87 (1.0;4.8) 0.008
nPCR: normalized protein catabolic rate, HOMA-IR: Homeostatic model assessment of insulin resistance, HOMA-AD: HOMA corrected by adiponectin, NEFA: non-
esterified fatty acids.
doi:10.1371/journal.pone.0109134.t003
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placebo phase (n = 5) versus subjects starting with the pioglitazone
phase (n = 4). The difference of pioglitazone-induced changes in
VAT for placebo vs pioglitazone starters was respectively of
(mean6SEM) 22.5 cm260.8 (213.7%63.6; p = 0.033)) and 2
2.1 cm260.8 (215.7% cm266.6; p = 0.147) suggesting that there
may be a carry-over effect of pioglitazone on VAT with a
consequent decreased difference in pioglitazone starters. The
differences of pioglitazone-induced changes in L/A ratio for
placebo or pioglitazone starters was respectively of (mean6SEM)
22.0360.87; p= 0.081 and 23.9361.5; p = 0.075. Thus, for
these parameters, having started with pioglitazone or placebo did
not have a significant impact on the pioglitazone-induced changes
compared to placebo. The numbers are indeed low and a much
larger study would be required to explore a possible carry-over
effect.
Safety
No significant side effects were observed during pioglitazone
therapy. Three patients were hospitalized for reasons unrelated
with the use of pioglitazone (see above) and were dropped out.
None of the patients developed signs of fluid retention and
interdialytic weight gains and UF volumes were comparable
between 2 phases.
Discussion
Insulin resistance is common in subjects with chronic kidney
disease and ESRD [27,28] and is associated with worse cardio-
vascular outcomes [29]. Mechanisms involved in the ‘‘uremic IR
state’’ are multiple [28]. Among them, increase in visceral fat,
change in adipokines, chronic inflammation, are modified by the
IS properties of pioglitazone in patients with normal renal function
[22]. Yet, these effects have not been studied in ESRD patients.
We therefore assessed whether pioglitazone alters the body fat
distribution in non diabetic ESRD subjects and whether it is
associated with an improvement in insulin sensitivity and
cardiometabolic risk factors.
We show that the short term use of pioglitazone is safe in ESRD
patients treated by maintenance dialysis and leads to a change in
body fat distribution. Although total body fat did not change, there
was a significant decrease in the VAT abdominal area, and in the
VAT/SAT ratio, indicating a redistribution of visceral fat toward
the subcutaneous area as demonstrated by the significant increase
in fat at the subscapular site. These changes in fat distribution were
associated with significant metabolic changes. The adipokine
profile changed favourably with a strong suppression of the high
L/A ratio to levels close to those found in the general population
[30]. HDL-cholesterol increased and there was a decrease in
inflammation. Hepatic insulin sensitivity significantly improved, as
documented by a lower fasting hepatic glucose production and an
increase in the hepatic insulin sensitivity index. This is consistent
with visceral fat playing a key role in the development of hepatic
insulin resistance and inflammation.
This study is the first to examine the effects of glitazones on
insulin sensitivity in ESRD subjects, using the HEGC technique.
HEGC is certainly the gold standard but is a complicated
procedure and in general, only surrogate indicators of IR have
been studied in previous reports. In non ESRD T2DM subjects,
pioglitazone primarily suppresses endogenous glucose production
(EGP) and some studies show an enhancement of insulin-induced
GDR [22,31,32]. Our study population differs from these studies
as none were T2DM, and all were on HD or PD and presented
with only slight or moderate IR [7,27]. Our results show that the
uremic state did not interfere with the favorable effects of
pioglitazone on body fat redistribution, adiponectin levels, EGP
and on inflammation. However, there were no alterations of
insulin-mediated glucose disposal. Since this is known to be
essentially mediated at high insulinemia, it indicates either no
effect of pioglitazone on muscle sensitivity in these patients, or
more likely, these non diabetic individuals have a smaller degree of
muscle insulin resistance compared to hepatic insulin resistance.
Pioglitazone lead to a suppression of the L/A ratio close to levels
found in the general population. The respective contribution from
subcutaneous and visceral fat to plasma leptin and adiponectin
levels is difficult to assess because many factors other than fat mass
may determine plasma leptin and adiponectin, especially in
dialysis patients. Furthermore a direct effect of pioglitazone on
the gene expression of adipokines has been demonstrated [33–35]
and may contribute to the observed findings in this study.
Although the relationship between adiponectin levels and visceral
fat mass is less clear in patients with chronic kidney disease than in
the general population, adiponectin has been inversely associated
with visceral fat in a cohort of patients with ESRD [36]. The
pioglitazone-induced increase in adiponectin found in this study
confirms previous findings [26,37,38] and could be related to the
decrease in visceral fat. This effect indeed can be considered as
positive as high stable adiponectin levels were found to be
associated with more favorable cardiovascular outcomes in
patients with ESRD [39]. The decrease in leptin with pioglitazone
is a new finding. Glitazones suppress leptin rodent gene expression
[33,34] and decrease by 40% leptin production from human
adipocyte cultures [40], but have no effect on plasma levels of
leptin [22]. However, the absence of an increase in plasma leptin
in those studies despite fat gain may mask a glitazone-induced
decrease in leptin production per unit of fat mass. In the current
study, the absence of gain in total fat mass with pioglitazone may
have facilitated the observed decrease in plasma leptin due to
downregulation of leptin gene expression. Indeed, the decrease in
plasma leptin is interesting, since leptin may be considered as a
uremic toxin in ESRD [41].
Figure 2. Individual changes in the leptin/adiponectin ratio.
doi:10.1371/journal.pone.0109134.g002
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While stratifying for dialysis modality, similar changes for body
composition and adipokines were observed in HD and PD
patients. These changes were significant for HD patients but not
for PD patients because of the small number of observations.
These results show that the effects of pioglitazone are independent
from dialysis modality.
This study has several strengths. First, we used the gold standard
methods to measure abdominal body fat distribution and insulin
sensitivity. Second, we used a double-blinded randomized design,
which enabled to compare the effects of pioglitazone versus
placebo in the same patient. The limitations of the study include
the small number of patients studied due to the complexity and
laborious nature of the procedure. However the sample size is
consistent with other studies having used this technique in this
population [7,14,15]. In addition, a possible carry-over effect
cannot be excluded. If all subjects had started with the placebo
phase, the effects of pioglitazone may have been even greater than
observed with this cross-over design.
In conclusion, 16 week treatment of pioglitazone in non diabetic
ESRD subjects on maintenance dialysis is well tolerated, reduces
visceral fat and improves the adipokine profile with a decrease in
hepatic insulin resistance. Whether these effects may improve the
Figure 3. Glucose metabolism during a 2-step HEGC, values at baseline and during insulin infusion rates of 0.03 mU/kg/min and
1 mU/kg/min. * p,0.05.
doi:10.1371/journal.pone.0109134.g003
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outcome of non diabetic ESRD patients still needs further
evaluation.
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